Description
In general, Pidotimod reinforces and stimulates both the immunological mechanisms involved in humoral immunity and those of cellular immunity mediated by T lymphocytes.
At the same time it stimulates and increases macrophage migration which is an essential and primordial point in the cellular immune response where it serves the purpose of obtaining adequate phagocytosis and elimination of the infectious germ. ADIMOD® has an effective and efficient prophylactic and protective action against infections by Gram positive and Gram negative germs that is not due to an intrinsic antimicrobial property of Pidotimod but to its immunostimulating effect.
ADIMOD® is almost completely absorbed when administered orally, with almost 93% of the unchanged product being recovered in the urine.
It is widely distributed throughout the body, being eliminated mainly through urine and little through faeces. It has a bioavailability of around 45% being dose dependent.
It undergoes little metabolism at the liver level so it is eliminated unchanged in the urine. No known metabolites. Its binding to plasma proteins is very poor, a fact that represents an advantage because it does not interfere with other medications. It has a half-life of approximately 4 hours. Its mechanism of action is unknown, but it is assumed that it acts through the stimulation and regulation of the cellular immune response through lymphocytes, mainly T lymphocytes. It also exerts an action on macrophages, stimulating their migration. It should be taken into account that the macrophage intervenes in the cellular immune response, hence the importance of the stimulation exerted by Pidotimod on the mobilization of macrophages to obtain adequate phagocytosis and elimination of the infectious germ. Pidotimod also has a protective effect since, without having a bactericidal or bacteriostatic activity, it stimulates the immune system in a global and sustained way, mainly macrophages.






Reviews
There are no reviews yet.